DermTech, Inc.

Equities

DMTK

US24984K1051

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.6031 ^USD	+3.02%		-6.35%	-65.54%

Apr. 22	North American Morning Briefing : Stock Futures -2-	DJ
Apr. 19	Lake Street Downgrades DermTech to Hold From Buy, Price Target is $0.63	MT

DermTech, Inc. Announces ECRI Complete Its Evaluation of the Pigmented Lesion Assay

June 14, 2023 at 08:00 am EDT

DermTech, Inc. announced that ECRI completed its evaluation of the Pigmented Lesion Assay (PLA), the foundational assay for the DermTech Melanoma Test (DMT) and changed its rating from Inconclusive to Somewhat Favorable.

Latest news about DermTech, Inc.

North American Morning Briefing : Stock Futures -2-	Apr. 22	DJ
Lake Street Downgrades DermTech to Hold From Buy, Price Target is $0.63	Apr. 19	MT
BTIG Downgrades DermTech to Neutral From Buy	Apr. 19	MT
DermTech Explores Strategic Alternatives to Boost Shareholder Value, Lays Off 100 Employees in Restructuring Plan	Apr. 18	MT
DermTech to Explore Strategic Alternatives and Implement Restructuring Plan	Apr. 17	CI
BTIG Adjusts DermTech's Price Target to $2 From $4, Maintains Buy Rating	Mar. 07	MT
Stephens Trims Price Target on DermTech to $1.50 From $2.50, Keeps Equalweight Rating	Mar. 05	MT
Transcript : DermTech, Inc., Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
DermTech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
DermTech, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Earnings Flash (DMTK) DERMTECH Reports Q4 Revenue $3.9M, vs. Street Est of $4.03M	Feb. 29	MT
Dermtech, Inc. Announces Cessation of Claudia Ibarra as Chief Operating Officer	Jan. 31	CI
DermTech Announces Positive Topline Results from A Study Evaluating the Dermtech Melanoma Test Across All Skin Types	Jan. 18	CI
DermTech, Inc. Simplifies the DermTech Melanoma Test by Discontinuing the Optional TERT Add-On Assay	Jan. 16	CI
Dermtech Announces Positive Topline Results from Trust 2 Study Evaluating the Dermtech Melanoma Test	Jan. 08	CI
Transcript : DermTech, Inc., Q3 2023 Earnings Call, Nov 02, 2023	Nov. 02
DermTech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Earnings Flash (DMTK) DERMTECH Posts Q3 Revenue $3.9M, vs. Street Est of $3.9M	Nov. 02	MT
DermTech Signs Contract With Highmark For Enhanced Access to DermTech Melanoma Test	23-09-19	MT
DermTech Inc Announces Contracts With Highmark for the Foundational Assay of Its DermTech Melanoma Test	23-09-19	CI
Dermtech Appoints Mark Aguillard as Chief Commercial Officer	23-09-11	CI
BTIG Adjusts Price Target on DermTech to $5 From $6, Maintains Buy Rating	23-08-07	MT
Transcript : DermTech, Inc., Q2 2023 Earnings Call, Aug 03, 2023	23-08-03
DermTech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Earnings Flash (DMTK) DERMTECH Posts Q2 Revenue $4M, vs. Street Est of $3.7M	23-08-03	MT

Chart DermTech, Inc.

Duration

Period

More charts

Company Profile

DermTech, Inc. is a molecular diagnostic company. The Company is engaged in developing and marketing non-invasive genomics tests to aid in the diagnosis and management of melanoma. Its technology enhances evaluation of lesions suspicious for melanoma using non-invasive sample collection and detecting genomic markers associated with melanoma to identify higher risk lesions or rule out melanoma with a 99% or higher negative predictive value (NPV). It offers DermTech Melanoma Test (the DMT), which is a non-invasive way to enhance evaluation of pigmented lesions suspicious for melanoma. Its genomics platform has been designed to work with its Smart Sticker, which provides an easy and non-invasive way to collect a skin sample, in contrast to the existing standard of care of using a scalpel to biopsy suspicious lesions. It also provides its research services and technology platform on a contract basis to pharmaceutical companies that use the technology to support their clinical trials.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-04-30 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for DermTech, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.6031 USD

Average target price

2.043 USD

Spread / Average Target

+238.80%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
DERMTECH, INC.	-65.54%	20.88M
BIOMÉRIEUX	+0.89%	12.8B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-10.29%	7.61B
AUTOBIO DIAGNOSTICS CO., LTD.	-1.16%	4.51B
LANTHEUS HOLDINGS, INC.	+5.74%	4.49B
10X GENOMICS, INC.	-50.70%	3.3B
ANDON HEALTH CO., LTD.	+12.21%	2.73B
VITROLIFE AB	-16.13%	2.02B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-11.50%	1.73B
MYRIAD GENETICS, INC.	-5.02%	1.64B

Diagnostic & Testing Substances